Overview

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Status:
Unknown status

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

Aprepitant is an oral neurokinin-1(NK-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (CINV). This phase II clinical trial was designed to evaluate the efficacy of aprepitant in the prevention of CINV with lung cancer patients receiving 3-day cisplatin-based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Aprepitant
BB 1101
Cisplatin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Fosaprepitant
Palonosetron